Skip to main content

Table 2 Annual ischemic stroke probability and severity by CHADS2 risk score, AF status and anticoagulant treatment received

From: Cost-effectiveness of an insertable cardiac monitor in a high-risk population in the US

CHADS2 score

No AF

Subclinical AF

No treatment (%)

Aspirin (%)

No treatment (%)

Aspirin (%)

NOAC*,† (%)

Warfarin* (%)

0‡

0.2

0.2

0.6

0.4

0.2

0.1

1‡

0.6

0.5

1.6

1.1

0.4

0.4

2

1.3

0.9

3.2

2.3

0.9

0.8

3

2.5

1.8

6.2

4.4

1.7

1.6

4

3.2

2.3

7.9

5.6

2.1

2.1

5

3.6

2.6

9.0

6.3

2.4

2.3

6

4.0

2.9

10.1

7.1

2.7

2.6

IS severity

Mild: 42%; Moderate: 26%; Severe: 10%; Fatal: 22%

  1. AF atrial fibrillation, IS ischemic stroke, NOAC non-vitamin K oral anticoagulants
  2. *NOAC was used as treatment in base case, and warfarin was considered in sensitivity analysis; †class-effect for NOAC was assumed by taking the average efficacy of apixaban, dabigatran (low and high dose), rivaroxaban, edoxaban (low and high dose) [14]. IS risk was adjusted by a factor of 1.46 (95% CI 0.8–2.16) per decade [13]; ‡Patients with CHADS2 ≤ 2were not included in our analysis
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us